Please try another search
For the three months ended 31 March 2022, Seoul Pharma Co., Ltd. revenues increased 56% to W12.55B. Net loss decreased 91% to W224.2M. Revenues reflect Tablet Finished Products segment increase of 46% to W9.08B, Hard Capsule segment increase of 67% to W1.77B, South Korea (Country) segment increase of 60% to W12.47B. Lower net loss reflects Finance income increase of 12% to W84M (income).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 12551.2 | 11549.37 | 10715.96 | 10154.55 |
Gross Profit | 7936.03 | 7399.38 | 6579.59 | 6785.18 |
Operating Income | 204.79 | -1843.08 | -697.61 | -1020.73 |
Net Income | -224.18 | -5106.35 | -852.07 | -1330.82 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 61074.6 | 62250.03 | 63619.31 | 62068.03 |
Total Liabilities | 42341.12 | 43292.37 | 39349.07 | 36945.72 |
Total Equity | 18733.48 | 18957.65 | 24270.24 | 25122.31 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -649.66 | -1674.58 | -1051.06 | -1388.41 |
Cash From Investing Activities | -483.34 | -1099.41 | -1839 | -1439.84 |
Cash From Financing Activities | -114.98 | 1535.13 | 1650.56 | -233.6 |
Net Change in Cash | -1225.79 | -1237.12 | -1183.83 | -3060.27 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review